# **MATERIAL SAFETY DATA SHEET # 1097**

**TESLASCAN**®

Page 1 of 4

Date: April 2003

# 1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

Product Name: Teslascan®

**Synonyms:** Teslascan<sup>®</sup> (mangafodipir) Infusion

**Applications:** An intravenous contrast agent for Magnetic Resonance Imaging (MRI)

Emergency Number: In an emergency, call 1-800-654-0118

Manufacturer: Amersham Health

101 Carnegie Center Princeton, NJ 08540

609-514-6000 or 1-800-654-0118

# 2. COMPOSITION, INFORMATION ON INGREDIENTS

<u>Ingredient Name</u> <u>CAS No.</u> <u>Percent by Weight</u>

Mangafodipir Trisodium 140678-14-4 1- 5%

Fodipir -- <0.1%

Water 7732-18-5 6-95%

# 3. HAZARDS IDENTIFICATION

A clear yellow aqueous solution. Presents little or no hazard if spilled or in a fire.

Risk Phrase: R61 - May cause harm to unborn child

Hazard Symbol: T - Toxic

**Potential Health** 

Effects: If entering the blood stream of a pregnant woman, it may harm the unborn child.

**Eyes:** May cause slight irritation.

**Skin:** Not an irritant.

**Ingestion:** No data available.

**Inhalation:** No data available.

#### 4. FIRST AID MEASURES

**Eyes:** Flush eyes with water for up to 15 minutes. If irritation persists, seek medical

attention.

**Skin:** Wash skin with soap and water.

**Ingestion:** Determine amount ingested and consult a physician.

# MATERIAL SAFETY DATA SHEET # 1097

**TESLASCAN**®

Page 2 of 4 Date: April 2003

**Inhalation:** Move person to fresh air and consult a physician.

#### 5. FIRE FIGHTING MEASURES

Flammable Properties: Nonflammable. This is an aqueous-based formulation.

**Extinguishing Media:** Use any extinguishing media appropriate for the surrounding fire.

Fire Fighting

**Procedures:** As for any fire, fire fighters should wear self-contained preathing apparatus

(SCBA) and full protective gear.

**Unusual Fire and** 

**Explosion Hazards:** None.

#### 6. ACCIDENTAL RELEASE MEASURES

Personal Precautions: Avoid contact with skin, eye, and clothing. Wear gloves. Wash after

cleaning spill.

**Spills:** Wipe up a spill with cloth or absorb on paper towels. Wash area with soap

and water. Take appropriate precautions when broken glass is present.

## 7. HANDLING AND STORAGE

**Handling:** Avoid contact with skin, eyes, and clothing. Wash after handling.

Storage: Store vial on side in original carton between 15 °C and 30 °C (59 °F and

86 ♥ F). Do not store vial upright. Upright storage may cause oxidation or discoloration. Do not freeze. Freezing may compromise the package

integrity.

## 8. EXPOSURE CONTROLS, PERSONAL PROTECTION

**Ventilation:** General ventilation is adequate.

**Protective Equipment:** Wear gloves (e.g., latex, PVC, polyethylene) which will prevent contact.

#### 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance: Clear liquid

Color: Yellow

**Solubility:** Very soluble in water

Specific Gravity: 1.03

**pH:** 8.4 to 9.2

Page 3 of 4

Date: April 2003

## 10. STABILITY AND REACTIVITY

Stability: Stable under normal and anticipated storage and handling conditions.

Conditions to Avoid: None.

**Materials to Avoid:** Avoid contact with strong oxidizing agents.

# 11. TOXICOLOGICAL INFORMATION

**Eye Effects:** Slightly irritating based on a rabbit eye irritation test. Slight conjunctival

redness was observed and cleared in 24 hours.

Skin Effects: Not a skin irritant based on rabbit irritation tests. No delayed contact

hypersensitivity was observed in Guinea pigs.

**Acute Effects:** Minimum lethal intravenous dose was greater than 2000 mg/kg in rats and mice.

Subchronic Effects: Repeated intravenous administration at a daily dose of 219 mg/kg resulted in

kidney and liver toxicity in rats and monkeys. The no observed effect level was 80 mg/kg for rats and 20 mg/kg for monkeys. The NOEL for repeat dose (21 day) dog study was 10 umol/kg. Target organs at higher doses (30 and

100 *u*mol/kg) were liver and kidney.

**Mutagenicity:** Not a mutagen based on negative results from a series of genotoxicity studies

(Ames test, chromosomal aberration in vitro, mammalian cell mutagenesis in

vitro, transformation in vitro, and mouse micronucleus).

**Teratogenicity:** Rats: Repeated intravenous administration to pregnant rats resulted in bone

malformations in fetuses. NOEL was 4 mg/kg.

Rabbits: Repeated intravenous administration to pregnant rabbits did not result in fetal malformations. Postimplantation losses were increased with

daily administration of 45 mg/kg. NOEL was 30 mg/kg.

Fertility: No adverse effects on the fertility of male or female rats after repeated

intravenous administration.

#### 12. ECOLOGICAL INFORMATION

The product is readily soluble in water. The active ingredient is rated as not **Summary:** 

> toxic to Daphnia or fish, but is toxic to algae. The no observed effect concentration for algae is 1.0 mg/l. The active ingredient does not readily

degrade and has a low potential for bioaccumulation.

### **Ecotoxicological Data:**

>2500 mg/lAcute toxicity  $LC_{50}$ 24 hours Daphnia

fish >1000 mg/l $LD_{50}$ 96 hours

# **MATERIAL SAFETY DATA SHEET # 1097**

**TESLASCAN** ®

Page 4 of 4

Date: April 2003

 $EC_{50}$  72 hours algae 21 mg/l Biodegradability BOD 28 days 3%

## 13. DISPOSAL CONSIDERATIONS

Disposal Methods: As with any waste, discharge, treatment, or disposal is subject to national,

state, and local laws and regulations. As of the MSDS revision date, this product does not meet the United States EPA definition of a hazardous waste.

#### 14. TRANSPORT INFORMATION

**General:** Transportation of this product is not subject to the United States Department

of Transportation Hazardous Materials Regulations.

## 15. REGULATORY INFORMATION

**US Federal** 

**Regulations:** Section 313: This product does **not** contain any toxic chemical subject to the

release reporting requirements of Section 313 of EPCRA and 40 CFR Part

372.

#### 16. OTHER INFORMATION

**Revision Date:** April 2003 (company name, emergency number and regulatory information)

**Disclaimer:** Although reasonable care has been taken in the preparation of this document,

we extend no warranties and make no representations as to the accuracy or completeness of the information contained therein, and assume no responsibility regarding the suitability of this information for the user's intended purposes or for the consequences of its use. Each individual should make a determination as to the suitability of the information for their

particular purpose(s).